Companies in #Chemotherapy-Induced Peripheral Neuropathy
Found 2 companies operating in this sector.
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline is led by ART27.13, a synthetic peripherally selective dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a for cancer-related anorexia, which in September 2026 reported nonclinical data in a diet-induced obesity model showing weight loss comparable to semaglutide as a monotherapy and roughly double that of semaglutide alone in combination. ART26.12 is a fatty acid binding protein 5 (FABP5) inhibitor in development for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, prostate and breast cancer, and pain, while ART12.11 is a cocrystal composition of cannabidiol and tetramethylpyrazine being evaluated for anxiety, depression, post-traumatic stress disorder, epilepsy and insomnia. The company was incorporated in 2011 as Reactive Medical Inc. and renamed Artelo Biosciences in April 2017.
MediciNova is a biopharmaceutical company developing small-molecule therapeutics licensed from Japanese originators for serious diseases with unmet medical need, and is dual-listed on Nasdaq and the Tokyo Stock Exchange. Its lead compound MN-166 (ibudilast) is an oral anti-inflammatory and neuroprotective agent in clinical development for amyotrophic lateral sclerosis (the Phase 2b/3 COMBAT-ALS registration trial enrolled 234 patients, with top-line data expected by year-end 2026), progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma and prevention of acute respiratory distress syndrome; an expanded-access program in ALS is supported by a $22 million NIH grant. The second compound, MN-001 (tipelukast), is an orally bioavailable small molecule in development for fibrotic and metabolic disorders including nonalcoholic fatty liver disease and hypertriglyceridemia. Management has framed 2026 as a data-driven year led by readouts from these two programs rather than by financing.